Videos

Bezlotoxumab is administered to prevent Clostridium difficile infection from recurring in patients who are receiving treatment for the infection and are at risk for recurrence.

Liz Oler, PharmD, discusses the short- and long-term impact of the PREP ACT on expanded privileges and practice changes within the pharmacy profession.

Ed Cohen, PharmD, FAPhA, leads a discussion in which panelists share thoughts on pharmacies being at the center of immunization services for the entire family.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discussed his history prior to joining NPC.

Theresa McArdle, MBA, senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the pandemic's impact on the legislative push to grant pharmacists provider status for Medicare Part B.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the updates in the prevention and treatment of cytokine release syndrome and neurologic toxicities for patients with multiple myeloma.

A panel of experts concludes by highlighting key advice for community pharmacists managing patients with heart failure and emphasizing the importance of communication between providers on the health care team.

Key opinion leaders in the pharmacologic management of heart failure share insights on optimizing care by using a patient-centered approach and shared decision-making.

Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA reviews the goals of pharmacologic maintenance of heart failure and comments on the importance of social determinants of health, health system efficiency, and patient education.

Experts share tips to help patients and pharmacies evaluate and participate in Prescription Discount Programs.

A discussion on some of the obstacles pharmacists may face and advice to improve the utility of Prescription Discount Programs.

Taylor M. Weis, PharmD, BCOP, discusses data on a BTK inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.

Experts discuss the results of a head-to-head trial of ibrutinib versus acalabrutinib in CLL and the cardiovascular toxicity associated with BTK inhibitors.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the changes that would take place if pharmacists were granted provider status for Medicare Part B.

Because there are no other available treatment options, Pamela Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families.

A panel of experts discuss how pharmacists can play a role in the nonpharmacologic treatment of dry eye disease.

Lisa M. Nijm, MD, JD, explains dry eye disease and its effects on a suffering patient.

Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.

Pharmacy Times interviewed Dennis O’Neill, president and board member of BIOMEDICAN, on the outlook around the future of biosynthesis therapeutics that use rare cannabinoids to treat a range of health issues, from mental health disorders to diabetes.

Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the emerging data around BCMA-targeted CAR T-cell therapy in multiple myeloma.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, outlined what has led to legislation granting pharmacists provider status gaining bipartisan support.

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.

Zydelig (idelalisib) is a kinase inhibitor approved in 2014 for 3 oncology indications.

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded by questions.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed what changes would be necessary to continue providing quality virtual health care to patients with diabetes.

Clive Ward Able, MD, BPharm, president of Clintell, consultant to NeonMind Inc, and a trained pharmacist and physician, discusses his research into the use of psychedelic compounds to treat obesity.